Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation

Transplantation

Volumn 81, Issue 6, 2006, Pages 927-933

  Tang, Wei ^a   Zhou, Ru ^a   Yang, Yang ^b   Li, Yuan Chao ^c   Yang, Yi Fu ^a   Zuo, Jian Ping ^a,b,c  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

(5R) 5 hydroxytriptolide; Cardiac transplantation; Chemokine; Immunosuppression

Indexed keywords

5 HYDROXYTRIPTOLIDE; ALLOANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CONCANAVALIN A; CYTOKINE; FINGOLIMOD; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MITOGENIC AGENT; RNA; TRIPTOLIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CARDIAC GRAFT REJECTION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FLOW CYTOMETRY; GRAFT SURVIVAL; HEART MUSCLE; HEART TRANSPLANTATION; HISTOLOGY; IMMUNOREACTIVITY; INFLAMMATORY CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; DITERPENES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CCR5; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33645641204     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203299.39843.d2     Document Type: Article

References (49)

1. Poston RS, Griffith BP. Heart transplantation. J Intensive Care Med 2004; 19(1): 3-12.
2. Canafax DM, Sutherland DE. Recent advances in solid organ transplantation. Pharmacotherapy 1987; 7 (2): S20-S23.
3. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 199; 353 (9158): 1083-1091.
4. Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl 1995; 50: S40-S44.
5. Krieger NR, Emre S. Novel immunosuppressants. Pediatr Transplant 2004; 8 (6): 594-599.
6. Lake KD, Canafax DM . Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrob Chemother 1995; 36 Suppl B: 11-22.
7. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10 (3): 136-1345.
8. Kahan BD . Cyclosporine. N Engl J Med 1989; 321 (25): 1725-1738.
9. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331 (6): 365-376.
10. Nickerson PW, Steurer W, Steiger J, Strom TB. In pursuit of the "holy grail": allograft tolerance. Kidney Int Suppl 1994; 44: S40-S49.
11. Ramgolam V, Ang SG, Lai YH, Loh CS, Yap HK. Traditional Chinese medicines as immunosuppressive agents. Ann Acad Med Singapore 2000; 29 (1): 11-16.
12. Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000; 26 (1): 29-50.
13. Guo JL, Yuan SX, Wang XC, Xu SX, LI DD. Tripterygium wilfordii Hook f in rheumatoid arthritis and ankylosing spondylitis. Preliminary report. Chin Med J (Engl). 1981; 94 (7): 405-412.
14. Qin WZ, Zhu GD, Yang SM, et al. Clinical observations on Tripterygium wilfordii in treatment of 26 cases of discoid lupus erythematosus. J Tradit Chin Med 1983; 3 (2): 131-132.
15. Asano K, Matsuishi J, Yu Y, et al. Suppressive effects of Tripterygium wilfordii Hook f., a traditional Chinese medicine, on collagen arthritis in mice. Immunopharmacology 1998; 39 (2): 117-126.
16. Fidler JM, Ku GY, Piazza D, et al. Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. III. Suppression of graft-versus-host disease in murine allogeneic bone marrow transplantation by the PG27 extract. Transplantation 2002; 74 (4): 445-457.
17. Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001; 42 (3): 253-265.
18. Gu WZ, Brandwein SR. Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol 1998; 20 (8): 389-400.
19. Hikim AP, Lue YH, Wang C, et al. Posttesticular antifertility action of triptolide in the male rat: evidence for severe impairment of cauda epididymal sperm ultrastructure. J Androl 2000; 21 (3): 431-437.
20. Lue Y, Sinha Hikim AP, Wang C, et al. Triptolide: a potential male contraceptive. J Androl 1998; 19 (4): 479-486.
21. Zhou R, Zhang F, He PL, et al. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int Immunopharmacol 2005; 5: 1895-1903.
22. Zhou R, Zheng SX, Tang W, et al. Inhibition of Inducible Nitric-Oxide Synthase Expression by (5R)-5-hydroxytriptolide (LLDT-8) in Interferon-{gamma} and Bacterial Lipopolysaccharide Stimulated Macrophages. J Pharmacol Exp Ther 2006; 316: 121-128.
23. Tang W, Yang Y, Zhang F, et al. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int Immunopharmacol 2005; 5: 1904-1913.
24. Fulmer RI, Cramer AT, Liebelt RA, Liebelt AG. Transplantation of Cardiac Tissue into the Mouse Ear. Am J Anat 1963; 113: 273-285.
25. Judd KP, Trentin JJ. Cardiac transplantation in mice. I. Factors influencing the take and survival of heterotopic grafts. Transplantation 1971; 11: 298-302.
26. Nikolova Z, Hof A, Baumlin Y, Hof RP. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. Transplantation 2001; 72: 168-171.
27. Babany G, Morris RE, Babany I, Kates RE. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine. J Pharmacol Exp Ther 1988; 244 (1): 259-262.
28. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-251.
29. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17 (3): 138-146.
30. Dallman MJ. Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 1993; 5 (5): 788-793.
31. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10 (5): 507-512.
32. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961-968.
33. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003; 75: 2044-2047.
34. Horiguchi K, Kitagawa-Sakakida S, Sawa Y, et al. Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 2002; 21: 1090-1100.
35. Lindholm A, Dahlqvist R, Groth GG, Sjoqvist F, et al. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990; 30: 443-452.
36. Wood KJ. Peripheral tolerance to alloantigen: strategies for the future. Eur J Immunogenet 1993; 20: 439-449.
37. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857-859.
38. Matas AJ, Gillingham KJ, Humar A, et al. Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation 2000; 69: 54-58.
39. Hall BM. Cells mediating allograft rejection. Transplantation 1991; 51: 1141-1151.
40. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992; 10: 333-358.
41. Billingham ME. Cardiac transplantation. In Sale GE, ed. The Pathology of Organ Transplantation. Boston: Butterworths, 1990: 133-152.
42. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281-1294.
43. Fishman MA, Perelson AS. Th1/Th2 cross regulation. J Theor Biol 1994; 170: 25-56.
44. Abehsira-Amar O, Gibert M, Joliy M, et al. IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells. J Immunol 1992; 148 (12): 3820-3829.
45. Mosmann TR. Directional release of lymphokines from T cells. Immunol Today 1988; 9: 306-307.
46. Krams SM, Falco DA, Villanueva JC, et al. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation 1992; 53: 151-156.
47. Whiting D, Hsieh G, Yun JJ, et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol 2004; 172: 7417-7424.
48. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199-1205.
49. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562-568.